查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1993161

抗逆转录病毒药物市场：2026-2032年全球市场预测（依药物类别、剂型、治疗方法、治疗阶段、病毒类型、患者族群、最终用户和分销管道划分）

Anti-Retroviral Drugs Market by Drug Class, Formulation, Therapy Type, Line Of Therapy, Virus Type, Patient Group, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，抗逆转录病毒药物市场价值将达到 327 亿美元，到 2026 年将成长至 341.9 亿美元，到 2032 年将达到 455 亿美元，复合年增长率为 4.83%。

主要市场统计数据
基准年 2025 327亿美元
预计年份：2026年 341.9亿美元
预测年份 2032 455亿美元
复合年增长率 (%) 4.83%

对抗逆转录病毒疗法的进展、医疗保健系统面临的挑战以及影响临床开发和商业性部署的实际优先事项进行策略概述。

要了解抗逆转录病毒疗法的现状，我们需要从两个观点来考虑：临床进展和计画实施。过去十年，随着药物技术的不断进步，抗逆转录病毒疗法已从复杂的联合治疗转变为简化的联合治疗和长效製剂，重塑了药物依从性和临床疗效的模式。同时，医疗系统和保险公司正在重新思考采购、分发和报销模式，以满足慢性病治疗的需求，同时确保不同患者群体的可近性和治疗的可负担性。在此背景下，我们需要一种能够将治疗方法创新与实际情况结合的策略整合。

重大的科学、交付和商业转折点将推动抗逆转录病毒疗法的创新和部署进入医疗保健系统整合的下一个阶段。

在抗逆转录病毒药物领域，变革正在发生，其影响范围已超越分子层面的创新，涵盖给药方法、诊断和服务设计等各个方面。在治疗方面，整合酶链转移抑制剂的成熟和联合治疗的策略性应用正在重新定义疗效标准，而对长效注射剂研发的关注也正在改变人们对药物依从性和治疗路径的预期。这些临床变化与诊断在治疗流程中的日益整合同步进行，从而能够更早发现抗药性并制定更精准的治疗方案转换策略。

关税制度和贸易措施的变化对抗逆转录病毒疗法的供应链策略、製造地和采购决策产生了哪些影响？

关税和贸易措施的实施可能会对抗抗逆转录病毒药物的整个供应链产生连锁反应，从原料药的采购到最终製剂的组装和分销，都可能受到影响。当进口成分被征收关税时，製造商通常会面临单位生产成本的增加，这会影响最终製剂和包装工序的位置决策。为此，一些公司可能会加快投资，在更靠近终端市场的地方建立产能；而另一些公司则可能会与供应商重新谈判合约条款，或寻求垂直整合，以降低跨境课税风险。

全面的细分情报，详细分析产品类型、给药途径、製剂亚型、医疗保健环境、分销管道、治疗线和病患小组如何影响策略决策。

从产品类型、给药途径、製剂细节、终端用户环境、分销管道、治疗定位和病患小组等角度进行市场細項分析，可以清楚揭示其商业性和临床意义。基于产品类型，CCR5拮抗剂、融合抑制剂、整合酶链转移抑制剂、非核苷类逆转录酶抑制剂、核苷类逆转录酶抑制剂和蛋白酶抑制剂等治疗类别各自具有独特的耐受性、合併症和安全性考量，这些因素会影响药物选择和临床给药顺序的决策。基于给药途径，口服和肠外给药之间的差异导致了药物依从性支持模式、给药部位要求以及医护人员使用长效注射剂的培训需求方面的差异。

美洲、欧洲、中东和非洲以及亚太地区之间存在的细微市场差异和战略意义，将对监管、製造和准入策略产生影响。

区域趋势对监管预期、支付方行为、生产策略和分销模式均有显着影响。在美洲，市场动态的特征是采购体係成熟、日益重视生命週期管理，以及公共和私人资金机制的整合，这些因素共同塑造了报销和存取模式。在该地区运营的製造商必须使其临床开发计划与支付方的证据要求相符，并製定既能反映都市区三级医疗市场需求又能兼顾广泛公共采购项目的定价策略。

产业领导者优先考虑的策略性企业方法和营运能力，旨在加速管道创新、确保供应并加强市场地位。

抗逆转录病毒药物领域的企业正透过创新、伙伴关係和营运优化相结合的方式来确保竞争优势。整个产业的投资重点正转向支持长效製剂、固定剂量组合药物和儿童适用剂型的平台投资。各公司也越来越多地寻求许可和共同开发契约，以加速获取新型给药系统和治疗监测工具等互补技术。

为研发和商业部门提供切实可行的多方面建议，以增强抗逆转录病毒疗法的临床差​​异化、供应韧性和支付方合作。

产业领导企业应采取多层次策略，同时兼顾临床差异化、供应链韧性和与支付者的合作。首先，他们必须优先开发能够解决药物依从性最大障碍的製剂和给药系统，包括投资研发长效注射剂和易于服用的儿童液体製剂，同时确保临床开发项目能够为支付方提供相关的疗效和安全性比较证据。其次，他们应实现原料药（API）和製剂来源多元化，协商灵活的供应商协议，并评估区域製造地，以降低贸易中断和关税风险，从而增强供应链韧性。

我们采用透明的混合方法研究途径，结合专家访谈、监管和临床资料审查以及情境分析，得出可操作的、基于证据的见解。

本执行摘要的调查方法融合了定性和定量方法，以确保研究结果的可靠性和适用性。主要研究包括对临床医生、采购负责人、生产企业高管和支付方进行半结构式访谈，以了解当前的实践模式、采购限制和推广驱动因素。次要研究则利用监管文件、临床试验註册资料、同侪审查的已发表文献和公共卫生指导文件，检验临床趋势、安全性概况和监管先例。资料三角验证用于协调不同观点，确保结论既反映临床实践，也反映商业性现实。

为了将治疗方面的进步转化为持久的公共卫生影响，我们需要整合强调临床创新、营运韧性和以支付方为中心的证据的结论。

总之，抗逆转录病毒疗法的格局正在被治疗方法、给药技术和服务模式的协同进步所重塑，而这一切都发生在一个可能对供应链经济产生重大影响的政策环境中。整合酶抑制剂、联合治疗和长效製剂的临床创新为提高患者依从性和治疗效果提供了明确的途径，但其商业化成功取决于能否将这些创新与製剂设计、给药方式和分销渠道策略等实际因素相结合。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：抗逆转录病毒药物市场：依药物类别划分

  • 核苷/核苷酸类逆转录酶抑制剂（NRTIs）
  • 非核苷类逆转录酶抑制剂（NNRTIs）
  • 蛋白酶抑制剂（PIs）
  • 整合酶链转移抑制剂（INSTIs）
  • 入侵抑制剂
    • CCR5拮抗剂
    • 融合抑制剂
  • 药物动力学增强剂

第九章：抗逆转录病毒药物市场（依剂型划分）

  • 口服
    • 药片
      • 速释片
      • 缓释片
    • 胶囊
    • 口服悬浮液
  • 注射剂
    • 长效注射药物
      • 用于肌肉注射的长效注射剂
      • 长效皮下注射
    • 静脉注射准备

第十章：依治疗方法的抗爱滋病毒药物市场

  • 治疗
    • 早期抗逆转录病毒疗法（ART）
    • 挽救/救援疗法
    • 治疗方法变更/维持治疗
  • 预防
    • 暴露前预防（PrEP）
    • 暴露后预防（PEP）
    • 预防母婴传染（PMTCT）

第十一章：抗逆转录病毒药物市场

  • 一线治疗
  • 二线治疗
  • 3 行或更多
  • 补救性治疗

第十二章 按病毒类型分類的抗逆转录病毒病毒药物市场

  • HIV-1
    • M组 HIV-1
    • 非M型HIV-1组（N、O、P）
  • HIV-2
  • HIV/HBV合併感染
  • HIV/HCV合併感染

第十三章：抗逆转录病毒药物市场

  • 成人版
  • 儿童

第十四章：抗逆转录病毒药物市场：依最终用户划分

  • 居家医疗
  • 医院
  • 专科诊所

第十五章：抗逆转录病毒药物市场：依通路划分

  • 医院药房
  • 零售药房
  • 网路药房
  • 政府采购计划
  • 非政府组织（NGO）管道

第十六章：抗逆转录病毒药物市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十七章：抗逆转录病毒药物市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十八章：抗逆转录病毒药物市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十九章：美国抗逆转录病毒药物市场

第二十章：中国抗逆转录病毒药物市场

第21章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AbbVie Inc.
  • Alkem Laboratories Ltd.
  • APOTEX INC.
  • Aurobindo Pharma Limited
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Emcure Pharmaceuticals Limited
  • F. Hoffmann-La Roche AG
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Hetero Drugs Limited
  • Johnson & Johnson
  • Jubilant Life Sciences Limited
  • Laurus Labs Limited
  • Lupin Limited
  • Macleods Pharmaceuticals Ltd
  • MacroGenics, Inc.
  • Merck & Co., Inc.
  • Micro Labs Limited
  • Novartis AG
  • Pfizer Inc.
  • Strides Pharma Science Limited
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Theratechnologies Inc.
  • Torrent Pharmaceuticals Ltd.
  • Viatris Inc.
  • ViiV Healthcare
  • Zhejiang Huahai Pharmaceutical Co., Ltd.
  • Zydus Lifesciences Limited
Product Code: MRR-1A1A064C02F2

The Anti-Retroviral Drugs Market was valued at USD 32.70 billion in 2025 and is projected to grow to USD 34.19 billion in 2026, with a CAGR of 4.83%, reaching USD 45.50 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 32.70 billion
Estimated Year [2026] USD 34.19 billion
Forecast Year [2032] USD 45.50 billion
CAGR (%) 4.83%

A strategic overview of anti-retroviral therapeutic advances, health system pressures, and practical priorities shaping clinical development and commercial execution

The introductory landscape for anti-retroviral therapeutics must be read through a dual lens of clinical advancement and programmatic delivery. Over the past decade, incremental pharmacologic refinements have transformed antiretroviral therapy from complex multi-pill regimens to simplified combinations and longer-acting modalities, reshaping adherence paradigms and clinical outcomes. Simultaneously, health systems and payers are recalibrating procurement, distribution, and reimbursement models to manage chronic care demands while preserving access and affordability for diverse patient populations. This context demands a strategic synthesis that aligns therapeutic innovation with operational realities.

This executive summary sets out to provide that synthesis. It outlines the major scientific and commercial inflection points affecting product development, regulatory strategy, and supply chain resilience. The narrative connects pharmacologic class dynamics with practical imperatives around formulation, route of administration, and patient-centered delivery. It also examines policy shifts and trade developments that can materially affect cost structures and manufacturing decisions.

Throughout, the focus remains on providing pragmatic insight for stakeholders who must balance clinical efficacy with scalability and access. Decision-makers will find an integrated view that links therapeutic differentiation to real-world deployment, enabling clearer prioritization of investments in research, manufacturing, and commercial execution.

Key scientific, delivery, and commercial inflection points driving the next phase of anti-retroviral therapeutic innovation and health system adoption

The anti-retroviral field is experiencing transformative shifts that extend beyond molecule-level innovation to include delivery, diagnostics, and service design. On the therapeutic front, the maturation of integrase strand transfer inhibitors and the strategic use of combination regimens have redefined efficacy benchmarks, while renewed R&D focus on long-acting parenteral formulations is changing adherence expectations and care pathways. These clinical shifts are occurring in parallel with diagnostics becoming more integrated into treatment algorithms, enabling earlier detection of resistance and more precise switching strategies.

Operationally, manufacturers and health system planners are adapting to a multipronged distribution reality in which hospital-based supply coexists with home care delivery and specialty clinic administration of injectables. This has accelerated investment in cold chain logistics, novel packaging formats, and patient support services to ensure continuity of therapy. Furthermore, regulatory frameworks are evolving to accommodate accelerated pathways for therapies addressing high unmet need and for new formulations intended to improve adherence.

Market access dynamics are concurrently reshaping product strategies. Pricing pressures and greater demand for cost-effective regimens are prompting differential pricing strategies and greater emphasis on lifecycle management. Partnerships between clinical developers, contract manufacturers, and distribution networks are becoming a dominant approach to manage capital intensity while preserving speed to market. Taken together, these shifts signify a landscape where scientific advancement, delivery innovation, and commercial agility jointly determine competitive positioning.

How evolving tariff regimes and trade measures are reshaping supply chain strategy, manufacturing footprints, and procurement decisions for anti-retroviral therapies

The imposition of tariffs and trade measures can create cascading effects across the anti-retroviral supply chain that extend from active pharmaceutical ingredient procurement to finished-dose assembly and distribution. When duties are applied to imported components, manufacturers commonly face higher unit production costs, which can influence decisions about where to site final formulation and packaging operations. In response, some firms accelerate capacity investments closer to end markets, while others renegotiate supplier terms or pursue vertical integration to reduce exposure to cross-border levies.

Tariff-driven cost pressure also amplifies the importance of supplier diversification and contract structure. Companies that maintain multi-sourced API supply chains or that leverage regional manufacturing partners are better positioned to mitigate the immediate impact of trade measures. Contractual clauses that allow for indexation to input costs or that provide for risk-sharing on tariff changes become more important in negotiations with third-party manufacturers and distributors.

Beyond direct cost implications, tariffs influence inventory strategies and working capital management. Organizations often build strategic buffers to smooth short-term supply disruptions and to provide negotiating leverage, but increased inventory levels carry their own financial and logistical costs. Health systems and procurement agencies may respond by emphasizing local procurement and supporting domestic manufacturing initiatives, which can improve supply security but require multi-year commitments and capital allocation. Ultimately, the cumulative impact of trade policy on anti-retroviral therapeutics underscores the need for flexible manufacturing footprints, robust supplier networks, and proactive commercial strategies that anticipate regulatory and tariff volatility.

Comprehensive segmentation intelligence detailing how product types, administration routes, formulation subtypes, care settings, distribution channels, therapy lines, and patient groups drive strategic decisions

Segmentation analysis reveals distinct commercial and clinical implications when the market is viewed through product types, administration routes, formulation specifics, end user settings, distribution channels, therapy line positioning, and patient groups. Based on product type, therapeutic categories such as Ccr5 antagonists, fusion inhibitors, integrase strand transfer inhibitors, non-nucleoside reverse transcriptase inhibitors, nucleoside reverse transcriptase inhibitors, and protease inhibitors each carry unique resistance profiles, combination potential, and safety considerations that inform formulary preferences and clinical sequencing decisions. Based on route of administration, the dichotomy between oral and parenteral delivery drives differences in adherence support models, administration site requirements, and training needs for providers administering long-acting injectables.

Based on formulation, the landscape encompasses injectable, oral liquid, and oral solid formats. The injectable class requires attention to both intravenous and subcutaneous administration pathways, with implications for clinic capacity and resource allocation. The oral liquid segment divides into solution and suspension presentations, which are critical for pediatric dosing accuracy and palatability. Oral solid forms split into capsule and tablet presentations, with downstream effects on fixed-dose combination strategies and blister or bottle packaging approaches. Based on end user, deployment patterns vary across home care, hospitals, and specialty clinics, each demanding tailored patient support, cold chain logistics where applicable, and different payer interactions.

Based on distribution channel, the roles of hospital pharmacies, online pharmacies, and retail pharmacies shape access, adherence interventions, and inventory policies, while each channel requires distinct regulatory compliance and dispensing workflows. Based on therapy line, first line, salvage therapy, and second line use cases dictate the clinical evidence required for adoption and determine where differentiated products can demonstrate value. Based on patient group, adult and pediatric populations necessitate investment in age-appropriate formulations, dosing regimens, and clinical safety data. Taken together, these segmentation lenses highlight where commercial and clinical priorities intersect, revealing clear levers for product differentiation, formulary positioning, and targeted service design.

Regional market nuances and strategic implications across the Americas, Europe Middle East & Africa, and Asia-Pacific that influence regulatory, manufacturing, and access strategies

Regional dynamics exert a powerful influence on regulatory expectations, payer behavior, manufacturing strategy, and distribution design. In the Americas, market dynamics are characterized by a mature procurement ecosystem, growing emphasis on lifecycle management, and a mix of public and private funding mechanisms that shape reimbursement and access. Manufacturers navigating this region must align clinical development plans with payer evidence requirements and design pricing strategies that reflect both urban tertiary care markets and broader public procurement programs.

Europe, Middle East & Africa presents a heterogeneous set of regulatory frameworks and procurement models. Countries within this combined region vary widely in their reliance on centralized tenders, local manufacturing preferences, and capacity to adopt novel delivery formats such as long-acting injectables. This heterogeneity requires segmented regulatory pathways and often necessitates partnerships with regional distributors or contract manufacturers to ensure market entry is commercially viable and operationally sustainable.

Asia-Pacific features a diverse mix of advanced biotech hubs, generics manufacturing centers, and rapidly evolving health systems that increasingly demand cost-effective regimens while also showing strong uptake of novel technologies where reimbursement pathways exist. Manufacturing proximity in this region can offer supply-chain advantages, but regulatory timelines and local clinical data requirements will influence launch sequencing. Across all regions, alignment with public health initiatives, capacity building for specialty clinic administration, and tailored patient support models remain essential to optimize coverage and adherence outcomes.

Strategic corporate approaches and operational capabilities that industry leaders are prioritizing to accelerate pipeline innovation, secure supply, and strengthen market positioning

Companies operating in the anti-retroviral space are adopting a mixture of innovation, partnership, and operational optimization to secure competitive advantage. Across the sector, investment focus is shifting toward platform investments that support long-acting formulations, fixed-dose combinations, and pediatric-appropriate presentations. Firms are increasingly pursuing licensing deals and co-development agreements to accelerate access to complementary technologies such as novel delivery systems and therapeutic drug monitoring tools.

Operationally, leaders are scaling contract manufacturing relationships to manage capital intensity while maintaining control over quality and supply security. Manufacturing strategies increasingly emphasize modular, geographically distributed facilities that can reduce tariff exposure and shorten delivery timelines to large public procurement programs. At the same time, commercial teams are prioritizing differentiated patient support services and digital adherence interventions to protect regimen persistence and to generate real-world evidence that supports reimbursement discussions.

Strategic M&A and selective in-licensing remain central tactics for companies seeking to broaden portfolios rapidly or to acquire complementary capabilities such as pediatric formulation expertise or biologics development experience. The emphasis on lifecycle management, including reformulations and indication expansions, is shaping R&D portfolios to maximize therapeutic longevity while addressing emerging resistance patterns and unmet patient needs.

Actionable, multi-dimensional recommendations for developers and commercial teams to strengthen clinical differentiation, supply resilience, and payer alignment for anti-retroviral offerings

Industry leaders should adopt a layered strategy that simultaneously addresses clinical differentiation, supply resilience, and payer alignment. First, prioritize development of formulations and delivery systems that address the most significant adherence barriers, including investment in long-acting parenteral options and palatable pediatric liquids, while ensuring that clinical development programs generate comparative effectiveness and safety evidence relevant to payers. Second, strengthen supply chain resilience by diversifying API and finished-dose sourcing, negotiating flexible supplier contracts, and evaluating regional manufacturing hubs to mitigate trade-related disruption and tariff exposure.

Third, engage payers and procurement stakeholders early to co-develop value demonstration frameworks that incorporate patient-reported outcomes and real-world adherence data. Fourth, build scalable patient support infrastructure that integrates digital adherence tools, remote monitoring, and training modules for clinicians administering injectables so that uptake is not constrained by service capacity. Fifth, structure commercial launches with channel-specific plans that reflect the unique needs of hospital pharmacies, online pharmacies, and retail dispensaries, and ensure that distribution partners understand cold chain and handling requirements where relevant.

Finally, pursue collaborative arrangements with public health agencies, non-governmental stakeholders, and clinical networks to expedite guideline inclusion and to support implementation studies. These combined actions will help align product innovation with the practical realities of delivery and reimbursement, improving the probability of sustained adoption across diverse care settings.

A transparent, mixed-methods research approach combining expert interviews, regulatory and clinical data review, and scenario analysis to produce actionable, evidence-based insights

The research methodology underpinning this executive summary integrates qualitative and quantitative approaches to ensure findings are robust and actionable. Primary research included semi-structured interviews with clinicians, procurement officers, manufacturing executives, and payers to capture current practice patterns, procurement constraints, and adoption drivers. Secondary research drew on regulatory filings, clinical trial registries, published peer-reviewed literature, and public health guidance documents to validate clinical trends, safety profiles, and regulatory precedents. Data triangulation was used to reconcile divergent perspectives and to ensure conclusions reflect both clinical practice and commercial reality.

Analytical frameworks included therapeutic class mapping, route-of-administration impact assessment, and segmentation crosswalks that linked formulation and distribution considerations to end user requirements. Scenario analysis was applied to explore the operational implications of trade policy shifts and tariff scenarios, focusing on supply chain adjustments rather than market sizing. Limitations include variability in regional regulatory timelines and the evolving nature of long-acting clinical evidence, which means that ongoing surveillance of clinical outcomes and policy shifts is necessary. Where assumptions were made, they were grounded in contemporary published sources and corroborated by expert interviews to preserve analytical integrity.

Concluding synthesis emphasizing the integration of clinical innovation, operational resilience, and payer-focused evidence to translate therapeutic advances into sustained public health impact

In conclusion, the anti-retroviral landscape is being reshaped by synergistic advances in therapeutics, delivery technologies, and service models, all occurring within a policy environment that can materially affect supply chain economics. Clinical innovation in integrase inhibitors, combination strategies, and long-acting formulations offers clear routes to improved adherence and outcomes, but successful commercialization depends on aligning those innovations with pragmatic considerations such as formulation design, administration capacity, and channel-specific distribution strategies.

Trade policy and tariff dynamics further underscore the need for flexible manufacturing strategies and supplier diversification to protect continuity of supply and to manage cost volatility. Segmentation insights emphasize that product success is contingent on precise alignment with patient groups, therapy lines, and end user capabilities, while regional heterogeneity requires tailored regulatory and commercial approaches. For industry leaders, the pathway to durable market impact lies in integrated planning that couples clinical differentiation with operational resilience and payer-focused evidence generation. This integrated approach will be essential to translate scientific advances into measurable public health gains and sustainable commercial outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Anti-Retroviral Drugs Market, by Drug Class

  • 8.1. Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs)
  • 8.2. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
  • 8.3. Protease Inhibitors (PIs)
  • 8.4. Integrase Strand Transfer Inhibitors (INSTIs)
  • 8.5. Entry Inhibitors
    • 8.5.1. CCR5 Antagonists
    • 8.5.2. Fusion Inhibitors
  • 8.6. Pharmacokinetic Enhancers

9. Anti-Retroviral Drugs Market, by Formulation

  • 9.1. Oral
    • 9.1.1. Tablets
      • 9.1.1.1. Immediate-Release Tablets
      • 9.1.1.2. Extended-Release Tablets
    • 9.1.2. Capsules
    • 9.1.3. Oral Suspensions
  • 9.2. Parenteral
    • 9.2.1. Long-Acting Injectables
      • 9.2.1.1. Intramuscular Long-Acting Injectables
      • 9.2.1.2. Subcutaneous Long-Acting Injectables
    • 9.2.2. Intravenous Formulations

10. Anti-Retroviral Drugs Market, by Therapy Type

  • 10.1. Treatment
    • 10.1.1. Initial Antiretroviral Therapy (ART)
    • 10.1.2. Salvage/Rescue Therapy
    • 10.1.3. Switch/Maintenance Therapy
  • 10.2. Prevention
    • 10.2.1. Pre-Exposure Prophylaxis (PrEP)
    • 10.2.2. Post-Exposure Prophylaxis (PEP)
    • 10.2.3. Prevention of Mother-to-Child Transmission (PMTCT)

11. Anti-Retroviral Drugs Market, by Line Of Therapy

  • 11.1. First-Line
  • 11.2. Second-Line
  • 11.3. Third-Line & Above
  • 11.4. Salvage Therapy

12. Anti-Retroviral Drugs Market, by Virus Type

  • 12.1. HIV-1
    • 12.1.1. Group M HIV-1
    • 12.1.2. Non-M HIV-1 Groups (N, O, P)
  • 12.2. HIV-2
  • 12.3. HIV/HBV Coinfection
  • 12.4. HIV/HCV Coinfection

13. Anti-Retroviral Drugs Market, by Patient Group

  • 13.1. Adult
  • 13.2. Pediatric

14. Anti-Retroviral Drugs Market, by End User

  • 14.1. Home Care
  • 14.2. Hospitals
  • 14.3. Specialty Clinics

15. Anti-Retroviral Drugs Market, by Distribution Channel

  • 15.1. Hospital Pharmacies
  • 15.2. Retail Pharmacies
  • 15.3. Online Pharmacies
  • 15.4. Government Procurement Programs
  • 15.5. Non-Governmental Organization Channels

16. Anti-Retroviral Drugs Market, by Region

  • 16.1. Americas
    • 16.1.1. North America
    • 16.1.2. Latin America
  • 16.2. Europe, Middle East & Africa
    • 16.2.1. Europe
    • 16.2.2. Middle East
    • 16.2.3. Africa
  • 16.3. Asia-Pacific

17. Anti-Retroviral Drugs Market, by Group

  • 17.1. ASEAN
  • 17.2. GCC
  • 17.3. European Union
  • 17.4. BRICS
  • 17.5. G7
  • 17.6. NATO

18. Anti-Retroviral Drugs Market, by Country

  • 18.1. United States
  • 18.2. Canada
  • 18.3. Mexico
  • 18.4. Brazil
  • 18.5. United Kingdom
  • 18.6. Germany
  • 18.7. France
  • 18.8. Russia
  • 18.9. Italy
  • 18.10. Spain
  • 18.11. China
  • 18.12. India
  • 18.13. Japan
  • 18.14. Australia
  • 18.15. South Korea

19. United States Anti-Retroviral Drugs Market

20. China Anti-Retroviral Drugs Market

21. Competitive Landscape

  • 21.1. Market Concentration Analysis, 2025
    • 21.1.1. Concentration Ratio (CR)
    • 21.1.2. Herfindahl Hirschman Index (HHI)
  • 21.2. Recent Developments & Impact Analysis, 2025
  • 21.3. Product Portfolio Analysis, 2025
  • 21.4. Benchmarking Analysis, 2025
  • 21.5. AbbVie Inc.
  • 21.6. Alkem Laboratories Ltd.
  • 21.7. APOTEX INC.
  • 21.8. Aurobindo Pharma Limited
  • 21.9. Boehringer Ingelheim GmbH
  • 21.10. Bristol-Myers Squibb Company
  • 21.11. Cipla Limited
  • 21.12. Dr. Reddy's Laboratories Ltd.
  • 21.13. Emcure Pharmaceuticals Limited
  • 21.14. F. Hoffmann-La Roche AG
  • 21.15. Gilead Sciences, Inc.
  • 21.16. GlaxoSmithKline plc
  • 21.17. Hetero Drugs Limited
  • 21.18. Johnson & Johnson
  • 21.19. Jubilant Life Sciences Limited
  • 21.20. Laurus Labs Limited
  • 21.21. Lupin Limited
  • 21.22. Macleods Pharmaceuticals Ltd
  • 21.23. MacroGenics, Inc.
  • 21.24. Merck & Co., Inc.
  • 21.25. Micro Labs Limited
  • 21.26. Novartis AG
  • 21.27. Pfizer Inc.
  • 21.28. Strides Pharma Science Limited
  • 21.29. Sun Pharmaceutical Industries Ltd.
  • 21.30. Teva Pharmaceutical Industries Ltd.
  • 21.31. Theratechnologies Inc.
  • 21.32. Torrent Pharmaceuticals Ltd.
  • 21.33. Viatris Inc.
  • 21.34. ViiV Healthcare
  • 21.35. Zhejiang Huahai Pharmaceutical Co., Ltd.
  • 21.36. Zydus Lifesciences Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ANTI-RETROVIRAL DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY VIRUS TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PATIENT GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 15. UNITED STATES ANTI-RETROVIRAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 16. CHINA ANTI-RETROVIRAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY NUCLEOSIDE/NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS (NRTIS), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY NUCLEOSIDE/NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS (NRTIS), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY NUCLEOSIDE/NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS (NRTIS), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NNRTIS), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NNRTIS), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NNRTIS), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PROTEASE INHIBITORS (PIS), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PROTEASE INHIBITORS (PIS), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PROTEASE INHIBITORS (PIS), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS (INSTIS), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS (INSTIS), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS (INSTIS), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ENTRY INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ENTRY INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ENTRY INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY CCR5 ANTAGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY CCR5 ANTAGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY CCR5 ANTAGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FUSION INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FUSION INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FUSION INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PHARMACOKINETIC ENHANCERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PHARMACOKINETIC ENHANCERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PHARMACOKINETIC ENHANCERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY TABLETS, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY IMMEDIATE-RELEASE TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY IMMEDIATE-RELEASE TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY IMMEDIATE-RELEASE TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY EXTENDED-RELEASE TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY EXTENDED-RELEASE TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY EXTENDED-RELEASE TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL SUSPENSIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL SUSPENSIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL SUSPENSIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY LONG-ACTING INJECTABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY LONG-ACTING INJECTABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY LONG-ACTING INJECTABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY LONG-ACTING INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INTRAMUSCULAR LONG-ACTING INJECTABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INTRAMUSCULAR LONG-ACTING INJECTABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INTRAMUSCULAR LONG-ACTING INJECTABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SUBCUTANEOUS LONG-ACTING INJECTABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SUBCUTANEOUS LONG-ACTING INJECTABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SUBCUTANEOUS LONG-ACTING INJECTABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INTRAVENOUS FORMULATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INTRAVENOUS FORMULATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INTRAVENOUS FORMULATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY TREATMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INITIAL ANTIRETROVIRAL THERAPY (ART), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INITIAL ANTIRETROVIRAL THERAPY (ART), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INITIAL ANTIRETROVIRAL THERAPY (ART), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SALVAGE/RESCUE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SALVAGE/RESCUE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SALVAGE/RESCUE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SWITCH/MAINTENANCE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SWITCH/MAINTENANCE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SWITCH/MAINTENANCE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PREVENTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PREVENTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PREVENTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PREVENTION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PRE-EXPOSURE PROPHYLAXIS (PREP), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PRE-EXPOSURE PROPHYLAXIS (PREP), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PRE-EXPOSURE PROPHYLAXIS (PREP), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY POST-EXPOSURE PROPHYLAXIS (PEP), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY POST-EXPOSURE PROPHYLAXIS (PEP), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY POST-EXPOSURE PROPHYLAXIS (PEP), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PREVENTION OF MOTHER-TO-CHILD TRANSMISSION (PMTCT), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PREVENTION OF MOTHER-TO-CHILD TRANSMISSION (PMTCT), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PREVENTION OF MOTHER-TO-CHILD TRANSMISSION (PMTCT), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FIRST-LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FIRST-LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FIRST-LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SECOND-LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SECOND-LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SECOND-LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY THIRD-LINE & ABOVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY THIRD-LINE & ABOVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY THIRD-LINE & ABOVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SALVAGE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SALVAGE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SALVAGE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY HIV-1, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY HIV-1, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY HIV-1, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY HIV-1, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY GROUP M HIV-1, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY GROUP M HIV-1, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY GROUP M HIV-1, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY NON-M HIV-1 GROUPS (N, O, P), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY NON-M HIV-1 GROUPS (N, O, P), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY NON-M HIV-1 GROUPS (N, O, P), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY HIV-2, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY HIV-2, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY HIV-2, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY HIV/HBV COINFECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY HIV/HBV COINFECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY HIV/HBV COINFECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY HIV/HCV COINFECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY HIV/HCV COINFECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY HIV/HCV COINFECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY GOVERNMENT PROCUREMENT PROGRAMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY GOVERNMENT PROCUREMENT PROGRAMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY GOVERNMENT PROCUREMENT PROGRAMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY NON-GOVERNMENTAL ORGANIZATION CHANNELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY NON-GOVERNMENTAL ORGANIZATION CHANNELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY NON-GOVERNMENTAL ORGANIZATION CHANNELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 160. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 161. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 162. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 163. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 164. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 165. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY TABLETS, 2018-2032 (USD MILLION)
  • TABLE 166. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 167. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY LONG-ACTING INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 168. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 170. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PREVENTION, 2018-2032 (USD MILLION)
  • TABLE 171. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 172. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY HIV-1, 2018-2032 (USD MILLION)
  • TABLE 174. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
  • TABLE 175. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. NORTH AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 180. NORTH AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 182. NORTH AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY TABLETS, 2018-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 184. NORTH AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY LONG-ACTING INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. NORTH AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PREVENTION, 2018-2032 (USD MILLION)
  • TABLE 188. NORTH AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. NORTH AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY HIV-1, 2018-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
  • TABLE 192. NORTH AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 194. LATIN AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 196. LATIN AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 198. LATIN AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY TABLETS, 2018-2032 (USD MILLION)
  • TABLE 200. LATIN AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY LONG-ACTING INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 202. LATIN AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 204. LATIN AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PREVENTION, 2018-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 206. LATIN AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY HIV-1, 2018-2032 (USD MILLION)
  • TABLE 208. LATIN AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 210. LATIN AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY TABLETS, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY LONG-ACTING INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PREVENTION, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY HIV-1, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY TABLETS, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY LONG-ACTING INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PREVENTION, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY HIV-1, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 245. MIDDLE EAST ANTI-RETROVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 246. MIDDLE EAST ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 247. MIDDLE EAST ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 248. MIDDLE EAST ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 249. MIDDLE EAST ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 250. MIDDLE EAST ANTI-RETROVIRAL DRUGS MARKET SIZE, BY TABLETS, 2018-2032 (USD MILLION)
  • TABLE 251. MIDDLE EAST ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 252. MIDDLE EAST ANTI-RETROVIRAL DRUGS MARKET SIZE, BY LONG-ACTING INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 253. MIDDLE EAST ANTI-RETROVIRAL DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. MIDDLE EAST ANTI-RETROVIRAL DRUGS MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 255. MIDDLE EAST ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PREVENTION, 2018-2032 (USD MILLION)
  • TABLE 256. MIDDLE EAST ANTI-RETROVIRAL DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 257. MIDDLE EAST ANTI-RETROVIRAL DRUGS MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
  • TABLE 258. MIDDLE EAST ANTI-RETROVIRAL DRUGS MARKET SIZE, BY HIV-1, 2018-2032 (USD MILLION)
  • TABLE 259. MIDDLE EAST ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
  • TABLE 260. MIDDLE EAST ANTI-RETROVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 261. MIDDLE EAST ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 262. AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 263. AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 264. AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 265. AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 266. AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 267. AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY TABLETS, 2018-2032 (USD MILLION)
  • TABLE 268. AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 269. AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY LONG-ACTING INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 270. AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 271. AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 272. AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PREVENTION, 2018-2032 (USD MILLION)
  • TABLE 273. AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 274. AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
  • TABLE 275. AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY HIV-1, 2018-2032 (USD MILLION)
  • TABLE 276. AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
  • TABLE 277. AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 278. AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 279. ASIA-PACIFIC ANTI-RETROVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 280. ASIA-PACIFIC ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 281. ASIA-PACIFIC ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 282. ASIA-PACIFIC ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 283. ASIA-PACIFIC ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 284. ASIA-PACIFIC ANTI-RETROVIRAL DRUGS MARKET SIZE, BY TABLETS, 2018-2032 (USD MILLION)
  • TABLE 285. ASIA-PACIFIC ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 286. ASIA-PACIFIC ANTI-RETROVIRAL DRUGS MARKET SIZE, BY LONG-ACTING INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 287. ASIA-PACIFIC ANTI-RETROVIRAL DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 288. ASIA-PACIFIC ANTI-RETROVIRAL DRUGS MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 289. ASIA-PACIFIC ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PREVENTION, 2018-2032 (USD MILLION)
  • TABLE 290. ASIA-PACIFIC ANTI-RETROVIRAL DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 291. ASIA-PACIFIC ANTI-RETROVIRAL DRUGS MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
  • TABLE 292. ASIA-PACIFIC ANTI-RETROVIRAL DRUGS MARKET SIZE, BY HIV-1, 2018-2032 (USD MILLION)
  • TABLE 293. ASIA-PACIFIC ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
  • TABLE 294. ASIA-PACIFIC ANTI-RETROVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 295. ASIA-PACIFIC ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 296. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 297. ASEAN ANTI-RETROVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 298. ASEAN ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 299. ASEAN ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 300. ASEAN ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 301. ASEAN ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 302. ASEAN ANTI-RETROVIRAL DRUGS MARKET SIZE, BY TABLETS, 2018-2032 (USD MILLION)
  • TABLE 303. ASEAN ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 304. ASEAN ANTI-RETROVIRAL DRUGS MARKET SIZE, BY LONG-ACTING INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 305. ASEAN ANTI-RETROVIRAL DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 306. ASEAN ANTI-RETROVIRAL DRUGS MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 307. ASEAN ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PREVENTION, 2018-2032 (USD MILLION)
  • TABLE 308. ASEAN ANTI-RETROVIRAL DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 309. ASEAN ANTI-RETROVIRAL DRUGS MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
  • TABLE 310. ASEAN ANTI-RETROVIRAL DRUGS MARKET SIZE, BY HIV-1, 2018-2032 (USD MILLION)
  • TABLE 311. ASEAN ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
  • TABLE 312. ASEAN ANTI-RETROVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 313. ASEAN ANTI-R